Myasthenia Gravis Clinical Trials

98 recruitingLast updated: June 9, 2026

There are 98 actively recruiting myasthenia gravis clinical trials across 36 countries. Studies span Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4, Early Phase 1. Top locations include Warsaw, Poland, Boca Raton, Florida, United States, Tampa, Florida, United States. Updated daily from ClinicalTrials.gov.


Myasthenia Gravis Trials at a Glance

98 actively recruiting trials for myasthenia gravis are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 3 with 20 trials, with the heaviest enrollment activity in Warsaw, Boca Raton, and Tampa. Lead sponsors running myasthenia gravis studies include argenx, Alexion Pharmaceuticals, Inc., and Huashan Hospital.

Browse myasthenia gravis trials by phase

Treatments under study

About Myasthenia Gravis Clinical Trials

Looking for clinical trials for Myasthenia Gravis? There are currently 55 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myasthenia Gravis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myasthenia Gravis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 98 trials

Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled4 locationsNCT07304154
Recruiting
Phase 3

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Myasthenia Gravis
Janssen Research & Development, LLC115 enrolled14 locationsNCT07217587
Recruiting
Phase 2Phase 3

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
argenx12 enrolled20 locationsNCT06392386
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled15 locationsNCT07294170
Recruiting
Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled13 locationsNCT07284420
Recruiting
Phase 3

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled129 locationsNCT06744920
Recruiting
Phase 2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis
Amgen15 enrolled3 locationsNCT06987539
Recruiting
Phase 3

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled124 locationsNCT06517758
Recruiting
Phase 3

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled83 locationsNCT07039916
Recruiting
Phase 4

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Myasthenia Gravis
UCB Biopharma SRL40 enrolled12 locationsNCT07246564
Recruiting
Phase 3

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled138 locationsNCT06463587
Recruiting
Phase 2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated30 enrolled9 locationsNCT07501702
Recruiting

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
AstraZeneca50 enrolled13 locationsNCT06909253
Recruiting
Phase 1Phase 2

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
Aurinia Pharmaceuticals Inc.81 enrolled3 locationsNCT07596901
Recruiting
Phase 2Phase 3

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled17 locationsNCT06193889
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled6 locationsNCT07247279
Recruiting

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

Generalized Myasthenia Gravis (gMG)gMG
argenx100 enrolled30 locationsNCT07595653
Recruiting
Phase 2Phase 3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 2Phase 3

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled14 locationsNCT06149559
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493